All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
At the 24th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Mohamad Mohty from the Hôpital Saint-Antoine, Paris, FR, about the role of autologous stem cell transplant (ASCT) in the future treatment of multiple myeloma (MM).
In this video, Professor Mohty summarizes the current status of ASCT in myeloma, stating it is a core part of the treatment pathway. He discuses smoldering myeloma, options for induction regimens, and then the potential future maintenance strategies that may impact patient care. Professor Mohty specifically refers to the potential of daratumumab, administered once every other month, to replace lenalidomide as maintenance therapy following ASCT. Professor Mohty concludes we will have to wait for the trial results, but that myeloma is "on the podium" at this year's EHA conference, with many interesting abstracts to be presented.
The role of autologous transplant in the future treatment of MM
Your opinion matters
EBMT 2019 | The evolution of induction regimens in multiple myeloma
Mohamad Mohty, explained the evolution of induction regimens in multiple myeloma (MM) and presented the results from a subgroup analysis of the real-world, clinical experience
Mohamad Mohty | EBMT 2019 | Optimal induction regimen for autologous stem cell transplant in MM
Mohamad Mohty | EBMT 2019 | Optimal induction regimen for autologous stem cell transplant in MM. Hospital Saint-Antoine and University Pierre & Marie...
Subscribe to get the best content related to multiple myeloma delivered to your inbox